Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Sanofi-Aventis S.A. ADR (SNY)

Sanofi-Aventis S.A. ADR (SNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 125,647,912
  • Shares Outstanding, K 2,537,829
  • Annual Sales, $ 50,266 M
  • Annual Income, $ 5,844 M
  • EBIT $ 10,835 M
  • EBITDA $ 16,021 M
  • 60-Month Beta 0.61
  • Price/Sales 2.73
  • Price/Cash Flow 7.84
  • Price/Book 1.62

Options Overview Details

View History
  • Implied Volatility 25.33% ( +4.57%)
  • Historical Volatility 21.32%
  • IV Percentile 60%
  • IV Rank 36.45%
  • IV High 39.81% on 04/24/24
  • IV Low 17.02% on 03/11/24
  • Put/Call Vol Ratio 18.50
  • Today's Volume 3,529
  • Volume Avg (30-Day) 855
  • Put/Call OI Ratio 0.78
  • Today's Open Interest 38,836
  • Open Int (30-Day) 38,476

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.91
  • Number of Estimates 4
  • High Estimate 0.97
  • Low Estimate 0.83
  • Prior Year 0.89
  • Growth Rate Est. (year over year) +2.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
47.57 +0.53%
on 11/14/24
55.12 -13.24%
on 10/16/24
-7.10 (-12.93%)
since 10/14/24
3-Month
47.57 +0.53%
on 11/14/24
58.97 -18.91%
on 09/04/24
-5.71 (-10.67%)
since 08/14/24
52-Week
45.13 +5.96%
on 11/15/23
58.97 -18.91%
on 09/04/24
+2.09 (+4.57%)
since 11/14/23

Most Recent Stories

More News
Trump Names Anti-Vaxxer Robert Kennedy As Health & Human Services Secretary: Here’s What It Means For Healthcare Stocks

Trump said his HHS Secretary nominee will ensure the public is protected from harmful substances that have aggravated the nation’s health crisis.

NVO : 105.32 (-1.49%)
IBB : 140.09 (-2.58%)
LLY : 786.23 (-3.15%)
MRNA : 39.77 (-5.62%)
AMGN : 295.93 (-1.83%)
XBI : 96.96 (-3.05%)
PFE : 26.02 (-2.62%)
BNTX : 103.56 (-7.10%)
SNY : 47.82 (-3.41%)
Top Analyst Reports for UnitedHealth, Bank of America & SAP

Wednesday, November 13, 2024The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth...

SONY : 18.49 (-0.05%)
SAP : 231.40 (+0.61%)
BAC : 45.90 (+0.07%)
BSX : 87.59 (-1.33%)
UNH : 593.15 (-2.10%)
SNY : 47.82 (-3.41%)
AstraZeneca Beats on Q3 Earnings, Ups 2024 View, to Invest $3.5B in US

AstraZeneca’s AZN third-quarter 2024 core earnings of $1.04 per American depositary share (ADS) beat the Zacks Consensus Estimate of $1.01 per share. Core earnings of $2.08 per share fell 20% year over...

AZN : 65.04 (-0.38%)
AMGN : 295.93 (-1.83%)
SNY : 47.82 (-3.41%)
Buy, Sell, or Hold AstraZeneca Stock? Key Tips Ahead of Q3 Earnings

Key TakeawaysZacks earnings estimates for AstraZeneca are currently at $4.06 per share. However, the earnings picture appears to brighten in 2025.The healthcare company has beaten earnings estimates in...

AZN : 65.04 (-0.38%)
NVO : 105.32 (-1.49%)
LLY : 786.23 (-3.15%)
SNY : 47.82 (-3.41%)
REGN Q3 Earnings and Revenues Beat on Strong Eylea HD & Dupixent Sales

Regeneron Pharmaceuticals, Inc. REGN reported better-than-expected third-quarter results despite lower sales from its lead drug, Eylea. Revenues climbed 11% to $3.72 billion, driven by growth in Eylea...

BAYRY : 5.4100 (+0.93%)
NVS : 103.40 (-0.44%)
REGN : 782.51 (-2.71%)
SNY : 47.82 (-3.41%)
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split

One of these players has split its stock in the past. The other one hasn't.

NVDA : 146.76 (+0.33%)
LLY : 786.23 (-3.15%)
GS : 588.61 (-0.94%)
CMG : 59.91 (+1.08%)
REGN : 782.51 (-2.71%)
AMGN : 295.93 (-1.83%)
WMT : 84.47 (-1.20%)
SNY : 47.82 (-3.41%)
Why Sanofi Stock Flew Higher on Friday

No investor can ignore a crushing bottom-line beat and raised profitability guidance.

SNY : 47.82 (-3.41%)
Pharma Stock Roundup: RHHBY Earnings, Drug Pipeline & Regulatory News

This week, Roche RHHBY announced its third-quarter and nine-month results. Sanofi SNY confirmed that it is holding exclusive talks with U.S. private equity company CD&R to sell a controlling stake in its...

AZN : 65.04 (-0.38%)
NVO : 105.32 (-1.49%)
RHHBY : 36.1400 (-2.38%)
PFE : 26.02 (-2.62%)
SNY : 47.82 (-3.41%)
Sanofi (SNY) Q3 2024 Earnings Call Transcript

SNY earnings call for the period ending September 30, 2024.

SNY : 47.82 (-3.41%)
Sanofi Q3 Earnings Beat, Dupixent, New Drugs, Vaccines Drive Sales

Sanofi SNY reported third-quarter 2024 adjusted earnings of $1.57 per American depositary share, which beat the Zacks Consensus Estimate of $1.35 per share. Earnings of €2.86 per share rose 12.2% on...

AZN : 65.04 (-0.38%)
LLY : 786.23 (-3.15%)
REGN : 782.51 (-2.71%)
SNY : 47.82 (-3.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme,...

See More

Key Turning Points

3rd Resistance Point 51.94
2nd Resistance Point 51.01
1st Resistance Point 49.42
Last Price 47.82
1st Support Level 46.90
2nd Support Level 45.97
3rd Support Level 44.38

See More

52-Week High 58.97
Fibonacci 61.8% 53.68
Fibonacci 50% 52.05
Fibonacci 38.2% 50.42
Last Price 47.82
52-Week Low 45.13

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar